Effect of Zinc and Ascorbic Acid on Symptom Length Among Patients With SARS-CoV-2 | Complementary and Alternative Medicine | JN Learning | AMA Ed Hub [Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
[Skip to Content Landing]

Effect of High-Dose Zinc and Ascorbic Acid Supplementation vs Usual Care on Symptom Length and Reduction Among Ambulatory Patients With SARS-CoV-2 InfectionThe COVID A to Z Randomized Clinical Trial

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME
Key Points

Question  Do high-dose zinc, high-dose ascorbic acid, and/or a combination of the 2 reduce the duration of symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)?

Findings  In this randomized clinical trial of 214 patients with confirmed SARS-CoV-2 infection receiving outpatient care, there was no significant difference in the duration of symptoms among the 4 groups.

Meaning  These findings suggest that treatment with zinc, ascorbic acid, or both does not affect SARS-CoV-2 symptoms.

Abstract

Importance  There is limited evidence regarding early treatment of novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to mitigate symptom progression.

Objective  To examine whether high-dose zinc and/or high-dose ascorbic acid reduce the severity or duration of symptoms compared with usual care among ambulatory patients with SARS-CoV-2 infection.

Design, Setting, and Participants  This multicenter, single health system randomized clinical factorial open-label trial enrolled 214 adult patients with a diagnosis of SARS-CoV-2 infection confirmed with a polymerase chain reaction assay who received outpatient care in sites in Ohio and Florida. The trial was conducted from April 27, 2020, to October 14, 2020.

Intervention  Patients were randomized in a 1:1:1:1 allocation ratio to receive either 10 days of zinc gluconate (50 mg), ascorbic acid (8000 mg), both agents, or standard of care.

Outcomes  The primary end point was the number of days required to reach a 50% reduction in symptoms, including severity of fever, cough, shortness of breath, and fatigue (rated on a 4-point scale for each symptom). Secondary end points included days required to reach a total symptom severity score of 0, cumulative severity score at day 5, hospitalizations, deaths, adjunctive prescribed medications, and adverse effects of the study supplements.

Results  A total of 214 patients were randomized, with a mean (SD) age of 45.2 (14.6) years and 132 (61.7%) women. The study was stopped for a low conditional power for benefit with no significant difference among the 4 groups for the primary end point. Patients who received usual care without supplementation achieved a 50% reduction in symptoms at a mean (SD) of 6.7 (4.4) days compared with 5.5 (3.7) days for the ascorbic acid group, 5.9 (4.9) days for the zinc gluconate group, and 5.5 (3.4) days for the group receiving both (overall P = .45). There was no significant difference in secondary outcomes among the treatment groups.

Conclusions and Relevance  In this randomized clinical trial of ambulatory patients diagnosed with SARS-CoV-2 infection, treatment with high-dose zinc gluconate, ascorbic acid, or a combination of the 2 supplements did not significantly decrease the duration of symptoms compared with standard of care.

Trial Registration  ClinicalTrials.gov Identifier: NCT04342728

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Accepted for Publication: January 9, 2021.

Published: February 12, 2021. doi:10.1001/jamanetworkopen.2021.0369

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Thomas S et al. JAMA Network Open.

Corresponding Author: Milind Y. Desai, MD, MBA, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Ave, Desk J1-5, Cleveland, OH 44195 (desaim2@ccf.org).

Author Contributions: Dr Desai had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Thomas, Patel, Bittel, Kumar, Mehra, McWilliams, Nissen, Desai.

Acquisition, analysis, or interpretation of data: Thomas, Patel, Bittel, Wolski, Wang, Kumar, Il’Giovine, Mehra, Nissen, Desai.

Drafting of the manuscript: Thomas, Patel, Bittel, Kumar, Il’Giovine, Mehra, Desai.

Critical revision of the manuscript for important intellectual content: All authors.

Statistical analysis: Wolski, Wang, Kumar, Desai.

Obtained funding: Thomas, Kumar, Desai.

Administrative, technical, or material support: Thomas, Bittel, Kumar, Nissen, Desai.

Supervision: Thomas, Bittel, Kumar, Il’Giovine, Nissen, Desai.

Conflict of Interest Disclosures: Dr McWilliams reported receiving consulting fees from Gilead Sciences outside the submitted work. Dr Desai reported receiving grants from Myokardia outside the submitted work and being supported by the Haslam Family Endowed Chair in Cardiovascular Medicine. No other disclosures were reported.

Data Sharing Statement: See Supplement 3.

Additional Contributions: Serpil Erzurum, MD, James Young, MD, Daniel Culver, MD, Joan Booth, RN, Nancy Obuchowski, MPH, and John Petrich, RPh (Cleveland Clinic), were members of the operational and safety monitoring board. They were not compensated for their time. We would like to thank Samantha Xu, BS (Cleveland Clinic), for help with logistics of study set-up and coordination. She was compensated for her time.

References
1.
Huang  C , Wang  Y , Li  X ,  et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.   Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5PubMedGoogle ScholarCrossref
2.
US Centers for Disease Control and Prevention. COVID-19. Accessed January 12, 2021. https://www.cdc.gov/coronavirus/2019-ncov/index.html
3.
Wu  Z , McGoogan  JM .  Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention.   JAMA. 2020;323(13):1239-1242. doi:10.1001/jama.2020.2648PubMedGoogle ScholarCrossref
4.
Gammoh  NZ , Rink  L .  Zinc in infection and inflammation.   Nutrients. 2017;9(6):E624. doi:10.3390/nu9060624PubMedGoogle Scholar
5.
Hemilä  H .  Vitamin C and infections.   Nutrients. 2017;9(4):E339. doi:10.3390/nu9040339PubMedGoogle Scholar
6.
Hemilä  H , Chalker  E .  Vitamin C for preventing and treating the common cold.   Cochrane Database Syst Rev. 2013;(1):CD000980. doi:10.1002/14651858.CD000980.pub4PubMedGoogle Scholar
7.
Singh  M , Das  RR .  Zinc for the common cold.   Cochrane Database Syst Rev. 2011;(2):CD001364. doi:10.1002/14651858.CD001364.pub3PubMedGoogle Scholar
8.
Eby  GA , Davis  DR , Halcomb  WW .  Reduction in duration of common colds by zinc gluconate lozenges in a double-blind study.   Antimicrob Agents Chemother. 1984;25(1):20-24. doi:10.1128/AAC.25.1.20PubMedGoogle ScholarCrossref
9.
Hemilä  H .  Zinc lozenges and the common cold: a meta-analysis comparing zinc acetate and zinc gluconate, and the role of zinc dosage.   JRSM Open. 2017;8(5):2054270417694291. doi:10.1177/2054270417694291PubMedGoogle Scholar
10.
Carr  AC .  Vitamin C administration in the critically ill: a summary of recent meta-analyses.   Crit Care. 2019;23(1):265. doi:10.1186/s13054-019-2538-yPubMedGoogle ScholarCrossref
11.
te Velthuis  AJ , van den Worm  SH , Sims  AC , Baric  RS , Snijder  EJ , van Hemert  MJ .  Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture.   PLoS Pathog. 2010;6(11):e1001176. doi:10.1371/journal.ppat.1001176PubMedGoogle Scholar
12.
Li  W , Moore  MJ , Vasilieva  N ,  et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus.   Nature. 2003;426(6965):450-454. doi:10.1038/nature02145PubMedGoogle ScholarCrossref
13.
Krenn  BM , Gaudernak  E , Holzer  B , Lanke  K , Van Kuppeveld  FJ , Seipelt  J .  Antiviral activity of the zinc ionophores pyrithione and hinokitiol against picornavirus infections.   J Virol. 2009;83(1):58-64. doi:10.1128/JVI.01543-08PubMedGoogle ScholarCrossref
14.
Hemilä  H .  Vitamin C, respiratory infections and the immune system.   Trends Immunol. 2003;24(11):579-580. doi:10.1016/j.it.2003.09.004PubMedGoogle ScholarCrossref
15.
Davelaar  FG , Bos  J .  Ascorbic acid and infectious bronchitis infections in broilers.   Avian Pathol. 1992;21(4):581-589. doi:10.1080/03079459208418879PubMedGoogle ScholarCrossref
16.
Weismann  K , Jakobsen  JP , Weismann  JE ,  et al.  Zinc gluconate lozenges for common cold: a double-blind clinical trial.   Dan Med Bull. 1990;37(3):279-281.PubMedGoogle Scholar
17.
Meltzer  DO , Best  TJ , Zhang  H , Vokes  T , Arora  V , Solway  J .  Association of vitamin D status and other clinical characteristics with COVID-19 test results.   JAMA Netw Open. 2020;3(9):e2019722. doi:10.1001/jamanetworkopen.2020.19722PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close